BMS Archive

Plant · Scientific monograph

Salvia officinalis

Common Sage / Garden Sage

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Cognitive Function Research, Cholinergic Research, Neurological & Cognitive Research, Oxidative Stress Research

Research overview

Historical use

Common sage is a Mediterranean Lamiaceae herb used in European, Middle Eastern, and monastic herbal traditions as a culinary aromatic and as a traditional preparation for digestion, sweating, mouth and throat complaints, and memory-related folk uses. Historical uses are ethnobotanical and do not establish clinical efficacy for cognition.

Modern research context

Human research on common sage is centered on cholinergic and cognitive outcomes. A small double-blind randomized placebo-controlled trial in mild-to-moderate Alzheimer's disease reported improvements on ADAS-cog and CDR-SB over 4 months using Salvia officinalis extract [1]. A systematic review of Salvia clinical trials found preliminary support for memory and cognitive outcomes, but emphasized small sample sizes, heterogeneous preparations, and limited replication [2]. Acute studies in healthy older adults reported memory and attention effects with anticholinesterase Salvia extracts [3]. A later healthy-adult trial used a proprietary combination of S. officinalis and S. lavandulaefolia, so those findings should not be attributed to S. officinalis alone [5].

Adverse effects

In the Alzheimer's disease RCT, adverse-event frequency was not greater than placebo and agitation was reported more often in the placebo group [1]. Broader Salvia tolerability concerns include gastrointestinal discomfort, dizziness, headache, and allergic reactions in susceptible individuals. Essential-oil or high-thujone preparations are not equivalent to the leaf extracts studied for cognition and may carry higher neurologic risk at excessive doses.

Contraindications

Avoid medicinal-dose preparations in known hypersensitivity to Salvia or other Lamiaceae plants. Use caution with cholinesterase inhibitors or anticholinergic medications because Salvia extracts can inhibit acetylcholinesterase in vitro and in clinical pharmacology contexts [2][3]. Essential-oil products and concentrated high-thujone preparations should be avoided in seizure disorders and during pregnancy unless specifically supervised; cognition trials do not establish use in these populations.

Clinical and phytochemical data

Used part

Leaf and aerial leaf extract; some cognition studies use standardized hydroalcoholic or anticholinesterase Salvia extracts. Combination products with Salvia lavandulaefolia must be treated separately.

Primary active compounds

  • Rosmarinic acid

  • Carnosic acid

  • Carnosol

  • 1,8-cineole

  • Alpha-thujone and beta-thujone

  • Ursolic acid

  • Flavonoids including luteolin and apigenin derivatives

Mechanism of action

Cognitive research focuses on cholinergic modulation, especially inhibition of acetylcholinesterase, which is pharmacologically relevant to attention and memory but remains preparation-dependent [2][3]. Polyphenols such as rosmarinic acid and carnosic acid are investigated for antioxidant effects through Nrf2 signaling and for suppression of inflammatory pathways such as NF-kB in preclinical models [4]. Monoterpenes in sage essential oil may contribute to central nervous system activity, but essential-oil chemistry differs from the leaf extracts used in most cognition trials [2][4].

Pharmacokinetics

Absorption

No comprehensive human pharmacokinetic profile is available for Salvia officinalis leaf extract as a whole. Rosmarinic acid and lipophilic diterpenes such as carnosic acid are orally absorbed to varying degrees, while volatile monoterpenes have faster absorption when used as essential-oil preparations; cognition trials do not provide a complete ADME dataset [2][4].

Distribution

Human tissue-distribution data for standardized Salvia officinalis extracts are not established. Lipophilic monoterpenes and diterpenes are expected to distribute into lipid-rich tissues, whereas phenolic acids circulate largely as conjugated metabolites; direct blood-brain distribution data for the complete extract are insufficient [4].

Metabolism

Phenolic constituents undergo phase II conjugation, including glucuronidation, sulfation, and methylation. Monoterpenes and diterpenes are expected to undergo hepatic oxidative metabolism; clinically meaningful CYP450 interaction data for Salvia officinalis cognition extracts are not established [4].

Excretion

Conjugated phenolic metabolites are eliminated primarily in urine and bile. Elimination half-lives for the complete extract and for cognition-relevant active fractions are not established in humans [4].

Safety and interactions

Drug interactions

Potential pharmacodynamic interaction with cholinesterase inhibitors, anticholinergic drugs, sedatives, and seizure-threshold-lowering drugs should be considered because anticholinesterase activity and thujone-containing essential-oil chemistry are documented for Salvia preparations [2][3][4]. No clinically graded interaction trials for Salvia officinalis cognition extracts were identified.

Toxicity

Leaf extracts used in short clinical studies were generally tolerated, but long-term controlled tolerability data are limited [1][2]. Concentrated essential oil is not interchangeable with leaf extract; thujone-rich oils can produce neurotoxicity at excessive exposure, including seizure risk, based on broader toxicology literature summarized in reviews [4].

Special precautions

Pregnancy

Insufficient human data for medicinal-dose Salvia officinalis extracts during pregnancy. Avoid concentrated extracts and essential-oil preparations as a precaution.

Lactation

Insufficient data on excretion of Salvia constituents into human milk. Avoid medicinal-dose preparations during lactation unless supervised.

Hepatic impairment

No formal studies in hepatic impairment. Because volatile and phenolic constituents undergo hepatic metabolism, use caution in severe liver disease.

Renal impairment

No formal studies in renal impairment. Phenolic metabolites are partly renally eliminated; no dose-adjustment guidance has been established.

Sources and references

  1. [1] - Akhondzadeh S et al. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther, 2003. PMID: 12605619
  2. [2] - Miroddi M et al. Systematic review of clinical trials assessing pharmacological properties of Salvia species on memory, cognitive impairment and Alzheimer's disease. CNS Neurosci Ther, 2014. PMID: 24836739
  3. [3] - Scholey AB et al. An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. Psychopharmacology (Berl), 2008. PMID: 18350281
  4. [4] - Lopresti AL. Salvia (Sage): A Review of its Potential Cognitive-Enhancing and Protective Effects. Drugs R D, 2017. PMID: 27888449
  5. [5] - Wightman EL et al. The Acute and Chronic Cognitive Effects of a Sage Extract: A Randomized, Placebo Controlled Study in Healthy Humans. Nutrients, 2021. PMID: 33466627

Additional source links

Continue browsing